Barry R. Davies

6.9k citations

99 papers · 3.4k indexed · h-index 33

Molecular Biology top 5%
Oncology top 2%
Pulmonary and Respiratory Medicine top 5%
Cancer Research top 5%
Immunology top 10%

Co-authors: Philip S. Rudland Roger Barraclough Armelle Logié Paul D. Smith Michael P.A. Davies Claire Crafter Fiona E. M. Gibbs Richard J. Edmondson
Topics: PI3K/AKT/mTOR signaling in cancer (26 papers)Prostate Cancer Treatment and Research (18 papers)Cancer, Hypoxia, and Metabolism (9 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Journal of Clinical Oncology Blood Cancer Research
Partner nations: United Kingdom United States Japan

In The Last Decade

Barry R. Davies

98 papers receiving 3.3k citations

Peers

Countries citing papers authored by Barry R. Davies

Since Specialization

Citations

This map shows the geographic impact of Barry R. Davies's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry R. Davies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry R. Davies more than expected).

Fields of papers citing papers by Barry R. Davies

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry R. Davies. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry R. Davies. The network helps show where Barry R. Davies may publish in the future.

Co-authorship network of co-authors of Barry R. Davies

This figure shows the co-authorship network connecting the top 25 collaborators of Barry R. Davies. A scholar is included among the top collaborators of Barry R. Davies based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry R. Davies. Barry R. Davies is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK 2022 ·ACS Medicinal Chemistry Letters ·Frederick W. Goldberg,Attilla Ting,David T. Beattie,Gillian M. Lamont,Charlene Fallan,M. Raymond V. Finlay,Beth Williamson,Marianne Schimpl,Alexander R. Harmer,(unknown),Pär Nordell,Anna Cronin,Mercedes Vázquez–Chantada,Derek Barratt,Antonio Ramos‐Montoya,Elaine Cadogan,Barry R. Davies	7
2	Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control 2021 ·Clinical Cancer Research ·Kyoko Nakamura,Ankur Karmokar,Paul Farrington,Neil H. James,Antonio Ramos‐Montoya,(unknown),Gareth Hughes,Tim Illidge,Elaine Cadogan,Barry R. Davies,Simon J. Dovedi,Viia Valge-Archer	43
3	Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model 2021 ·British Journal of Cancer ·Yanyan Jiang,Jennifer Martin,(unknown),(unknown),Paul Kinchesh,Stuart Gilchrist,Veerle Kersemans,Sean Smart,James Thompson,Mark A. Hill,Mark J. O’Connor,Barry R. Davies,Anderson J. Ryan	4
4	Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy 2019 ·JCI Insight ·Marco A. De Velasco,(unknown),Kazuko Sakai,Yuji Hatanaka,Barry R. Davies,(unknown),Stéphanie Klein,Young Soo Kim,A. Robert MacLeod,Koichi Sugimoto,Kazuhiro Yoshikawa,Kazuto Nishio,Hirotsugu Uemura	31
5	The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor 2019 ·Journal of Medicinal Chemistry ·Frederick W. Goldberg,M. Raymond V. Finlay,Attilla Ting,David T. Beattie,Gillian M. Lamont,Charlene Fallan,Gail L. Wrigley,Marianne Schimpl,Martin Howard,Beth Williamson,Mercedes Vázquez–Chantada,Derek Barratt,Barry R. Davies,Elaine Cadogan,Antonio Ramos‐Montoya,Emma Dean	66
6	Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547 2016 ·Molecular Cancer Therapeutics ·Oona Delpuech,Claire Rooney,Lorraine Mooney,Dawn Baker,Robert A. Shaw,Michael Dymond,Dennis Wang,Pei Zhang,Sarah Cross,Margaret H. Veldman-Jones,Joanne Wilson,Barry R. Davies,Jonathan R. Dry,Elaine Kilgour,Paul D. Smith	18
7	AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo 2015 ·Molecular Cancer Therapeutics ·Ricardo Ribas,Sunil Pancholi,Stephanie K. Guest,Elisabetta Marangoni,Qiong Gao,Aurélie Thuleau,Nikiana Simigdala,Urszula M. Polanska,(unknown),Aradhana Rani,Gianmaria Liccardi,Stephen Johnston,Barry R. Davies,Mitch Dowsett,Lesley‐Ann Martin	49
8	Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors 2015 ·Molecular Cancer Therapeutics ·Barry R. Davies,(unknown),Armelle Logié,Claire Crafter,Lyndsey Hanson,Vivien N. Jacobs,Neil H. James,Philippa Dudley,Kelly Jacques,Brendon Ladd,Celina M. D’Cruz,Michael Zinda,Justin P.O. Lindemann,Makoto Kodaira,Kenji Tamura,Emma Jenkins	54
9	AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules 2015 ·Molecular Cancer Therapeutics ·Sylvie M. Guichard,Jon Curwen,Teeru Bihani,Celina M. D’Cruz,James Yates,Michael Grondine,Zoë Howard,Barry R. Davies,Graham Bigley,Teresa Klinowska,Kurt G. Pike,Martin Pass,Christine M. Chresta,Urszula M. Polanska,Robert McEwen,Oona Delpuech,Stephen Green,Sabina Cosulich	103
10	Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models 2015 ·International Journal of Oncology ·Claire Crafter,John P. Vincent,Eric Tang,Phillippa Dudley,Neil H. James,Teresa Klinowska,Barry R. Davies	31
11	Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo 2013 ·Molecular Cancer Therapeutics ·Christian Thomas,François Lamoureux,Claire Crafter,Barry R. Davies,Eliana Beraldi,Ladan Fazli,Soojin Kim,Daksh Thaper,Martin Gleave,Amina Zoubeidi	115
12	Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055) 2012 ·Cancer Research ·Sarah V. Holt,Armelle Logié,Barry R. Davies,Denis Alférez,Sarah Runswick,Sarah E. Fenton,Christine M. Chresta,Yi Gu,Jingchuan Zhang,Yi‐Long Wu,Robert W. Wilkinson,Sylvie M. Guichard,Paul D. Smith	70
13	Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363 2012 ·Clinical Cancer Research ·François Lamoureux,Christian Thomas,Claire Crafter,Masafumi Kumano,Fan Zhang,Barry R. Davies,Martin Gleave,Amina Zoubeidi	89
14	Activity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in combination with standard and approved therapies: impact of in vivo sequencing of drug administration 2008 ·Cancer Research ·Robert W. Wilkinson,Armelle Logié,(unknown),Nicola J. Curtis,(unknown),Barry R. Davies,Jennifer S. McKay,Paul D. Smith	1
15	Celecoxib has Potent Antitumour Effects as a Single Agent and in Combination with BCG Immunotherapy in a Model of Urothelial Cell Carcinoma 2008 ·European Urology ·Simon J. Dovedi,John A. Kirby,Barry R. Davies,Hing Y. Leung,John D. Kelly	32
16	AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models 2007 ·Molecular Cancer Therapeutics ·Barry R. Davies,Armelle Logié,Jennifer S. McKay,Paul Martin,(unknown),Richard O. Jenkins,Mark Cockerill,(unknown),Paul D. Smith	322
17	Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines 2006 ·Growth Factors ·Islay Steele,Richard J. Edmondson,Hing Y. Leung,Barry R. Davies	22
18	Galectin‐3 does not reliably distinguish benign from malignant thyroid neoplasms 2004 ·Histopathology ·(unknown),(unknown),Ralph BouHaidar,Sarah J. Johnson,J. A. Wilson,Barry R. Davies,Thomas W. J. Lennard	79
19	Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy 2003 ·British Journal of Cancer ·Helen Atkins,Barry R. Davies,John A. Kirby,(unknown)	28
20	Transfection of rat ovarian surface epithelium with erb-B2/neu induces transformed phenotypes in vitro and the tumorigenic phenotype in vivo. 1998 ·PubMed ·Barry R. Davies,Nelly Auersperg,Sally Worsley,B. A. J. Ponder	17

About Barry R. Davies

Barry R. Davies is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 99 papers that have together received 3.4k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (26 papers), Prostate Cancer Treatment and Research (18 papers) and Cancer, Hypoxia, and Metabolism (9 papers). The work is most often cited by research in Cancer Research (584 citations), Oncology (1.0k citations) and Molecular Biology (2.1k citations). Barry R. Davies has collaborated with scholars based in United Kingdom, United States and Japan. Frequent co-authors include Philip S. Rudland, Roger Barraclough, Armelle Logié, Paul D. Smith, Michael P.A. Davies, Claire Crafter, Fiona E. M. Gibbs, Richard J. Edmondson, Paul Martin and Jennifer S. McKay. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact